RU2706787C2 - Модель сухого кератоконъюнктивита на животных и способы применения таких животных - Google Patents
Модель сухого кератоконъюнктивита на животных и способы применения таких животных Download PDFInfo
- Publication number
- RU2706787C2 RU2706787C2 RU2017118978A RU2017118978A RU2706787C2 RU 2706787 C2 RU2706787 C2 RU 2706787C2 RU 2017118978 A RU2017118978 A RU 2017118978A RU 2017118978 A RU2017118978 A RU 2017118978A RU 2706787 C2 RU2706787 C2 RU 2706787C2
- Authority
- RU
- Russia
- Prior art keywords
- eye
- scopolamine
- animal
- benzalkonium chloride
- administered
- Prior art date
Links
- 206010023332 keratitis Diseases 0.000 title claims abstract description 84
- 201000010666 keratoconjunctivitis Diseases 0.000 title claims abstract description 84
- 241001465754 Metazoa Species 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 53
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 88
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 88
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 61
- 229960002646 scopolamine Drugs 0.000 claims abstract description 56
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims abstract description 54
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims abstract description 54
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims abstract description 54
- 241000283984 Rodentia Species 0.000 claims abstract description 41
- 239000012530 fluid Substances 0.000 claims abstract description 40
- 238000004519 manufacturing process Methods 0.000 claims abstract description 39
- 238000012360 testing method Methods 0.000 claims abstract description 37
- 239000003814 drug Substances 0.000 claims abstract description 26
- 230000007794 irritation Effects 0.000 claims abstract description 19
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 18
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 230000035168 lymphangiogenesis Effects 0.000 claims abstract description 10
- 230000033115 angiogenesis Effects 0.000 claims abstract description 6
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims abstract 16
- 238000010186 staining Methods 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 22
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 13
- 210000004969 inflammatory cell Anatomy 0.000 claims description 12
- 102000004127 Cytokines Human genes 0.000 claims description 11
- 108090000695 Cytokines Proteins 0.000 claims description 11
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 11
- 206010013774 Dry eye Diseases 0.000 claims description 11
- 230000000770 proinflammatory effect Effects 0.000 claims description 10
- 239000007924 injection Substances 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 7
- 238000007910 systemic administration Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 238000010171 animal model Methods 0.000 abstract description 5
- 239000000126 substance Substances 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 2
- 231100000915 pathological change Toxicity 0.000 abstract 1
- 230000036285 pathological change Effects 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000001508 eye Anatomy 0.000 description 69
- STECJAGHUSJQJN-VJQRDGCPSA-N chembl3084722 Chemical compound C1([C@@H](CO)C(=O)O[C@@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-VJQRDGCPSA-N 0.000 description 40
- 238000011282 treatment Methods 0.000 description 32
- 101000799554 Homo sapiens Protein AATF Proteins 0.000 description 29
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 26
- 210000004087 cornea Anatomy 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 238000002513 implantation Methods 0.000 description 12
- 210000004561 lacrimal apparatus Anatomy 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 9
- 210000001365 lymphatic vessel Anatomy 0.000 description 9
- 208000021386 Sjogren Syndrome Diseases 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 230000003204 osmotic effect Effects 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 239000000812 cholinergic antagonist Substances 0.000 description 5
- 201000000159 corneal neovascularization Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 4
- 241000566150 Pandion haliaetus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 239000002085 irritant Substances 0.000 description 4
- 231100000021 irritant Toxicity 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- -1 scope Chemical compound 0.000 description 4
- 238000004088 simulation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 241000283074 Equus asinus Species 0.000 description 3
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 3
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 3
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 206010015943 Eye inflammation Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 206010047571 Visual impairment Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NJDNXYGOVLYJHP-UHFFFAOYSA-L disodium;2-(3-oxido-6-oxoxanthen-9-yl)benzoate Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=CC(=O)C=C2OC2=CC([O-])=CC=C21 NJDNXYGOVLYJHP-UHFFFAOYSA-L 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 208000029257 vision disease Diseases 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 239000012110 Alexa Fluor 594 Substances 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010015946 Eye irritation Diseases 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 208000018565 Hemochromatosis Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- HOBWAPHTEJGALG-JKCMADFCSA-N [(1r,5s)-8-methyl-8-azoniabicyclo[3.2.1]octan-3-yl] 3-hydroxy-2-phenylpropanoate;sulfate Chemical compound [O-]S([O-])(=O)=O.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1.C([C@H]1CC[C@@H](C2)[NH+]1C)C2OC(=O)C(CO)C1=CC=CC=C1 HOBWAPHTEJGALG-JKCMADFCSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960002028 atropine sulfate Drugs 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 231100000013 eye irritation Toxicity 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000056845 human AATF Human genes 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000002973 irritant agent Substances 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000004796 pathophysiological change Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 210000005233 tubule cell Anatomy 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- G—PHYSICS
- G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
- G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
- G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
- G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/20—Animals treated with compounds which are neither proteins nor nucleic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Medical Informatics (AREA)
- Educational Technology (AREA)
- Theoretical Computer Science (AREA)
- Educational Administration (AREA)
- Business, Economics & Management (AREA)
- Pure & Applied Mathematics (AREA)
- Mathematical Physics (AREA)
- Mathematical Optimization (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086263P | 2014-12-02 | 2014-12-02 | |
| US62/086,263 | 2014-12-02 | ||
| PCT/US2015/063084 WO2016089807A1 (en) | 2014-12-02 | 2015-12-01 | Animal model for dry eye and methods of use of such animals |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2017118978A RU2017118978A (ru) | 2019-01-09 |
| RU2017118978A3 RU2017118978A3 (https=) | 2019-06-04 |
| RU2706787C2 true RU2706787C2 (ru) | 2019-11-21 |
Family
ID=55024246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017118978A RU2706787C2 (ru) | 2014-12-02 | 2015-12-01 | Модель сухого кератоконъюнктивита на животных и способы применения таких животных |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20170360013A1 (https=) |
| EP (1) | EP3226853B1 (https=) |
| JP (1) | JP6692808B2 (https=) |
| KR (1) | KR20170100483A (https=) |
| CN (1) | CN107106553A (https=) |
| AU (1) | AU2015355169A1 (https=) |
| CA (1) | CA2967432A1 (https=) |
| ES (1) | ES2759729T3 (https=) |
| IL (1) | IL252077A0 (https=) |
| MX (1) | MX2017007295A (https=) |
| RU (1) | RU2706787C2 (https=) |
| SG (1) | SG11201703572SA (https=) |
| WO (1) | WO2016089807A1 (https=) |
| ZA (1) | ZA201703052B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190240251A1 (en) * | 2016-10-14 | 2019-08-08 | i.com medical GmbH | Method for establishing, restoring, and preserving homeostasis of the ocular surface |
| CN112292135A (zh) | 2018-04-18 | 2021-01-29 | I.Com医疗有限责任公司 | 用于治疗和预防严重眼表疾病的高分子量透明质酸 |
| US12268706B2 (en) | 2019-01-31 | 2025-04-08 | i.com medical GmbH | Hyaluronic acid for relief of idiopathic ocular pain |
| KR102429281B1 (ko) * | 2020-05-25 | 2022-08-05 | (주)노바셀테크놀로지 | 신규 안구건조증 치료용 약학적 조성물 |
| CN113519461A (zh) * | 2021-07-06 | 2021-10-22 | 江西中洪博元生物技术有限公司 | 伴刀豆球蛋白a诱导的小鼠干眼症模型的构建方法及应用 |
| WO2023215261A1 (en) * | 2022-05-02 | 2023-11-09 | Ocular Services On Demand, Llc | Mammalian eye models |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012013884A1 (fr) * | 2010-07-29 | 2012-02-02 | Laboratoires Fournier Sa | Composes pour le traitement/la prevention des maladies inflammatoires oculaires |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2384679A1 (en) * | 1999-09-08 | 2001-03-15 | Srinivasan Venkateshwaran | Using quaternary ammonium salts for transdermal drug delivery |
-
2015
- 2015-12-01 JP JP2017525337A patent/JP6692808B2/ja not_active Expired - Fee Related
- 2015-12-01 CA CA2967432A patent/CA2967432A1/en not_active Abandoned
- 2015-12-01 KR KR1020177012469A patent/KR20170100483A/ko not_active Withdrawn
- 2015-12-01 ES ES15816590T patent/ES2759729T3/es active Active
- 2015-12-01 AU AU2015355169A patent/AU2015355169A1/en not_active Abandoned
- 2015-12-01 WO PCT/US2015/063084 patent/WO2016089807A1/en not_active Ceased
- 2015-12-01 RU RU2017118978A patent/RU2706787C2/ru not_active IP Right Cessation
- 2015-12-01 US US15/532,527 patent/US20170360013A1/en not_active Abandoned
- 2015-12-01 SG SG11201703572SA patent/SG11201703572SA/en unknown
- 2015-12-01 EP EP15816590.2A patent/EP3226853B1/en active Active
- 2015-12-01 MX MX2017007295A patent/MX2017007295A/es unknown
- 2015-12-01 CN CN201580065760.3A patent/CN107106553A/zh active Pending
-
2017
- 2017-05-03 IL IL252077A patent/IL252077A0/en unknown
- 2017-05-03 ZA ZA2017/03052A patent/ZA201703052B/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012013884A1 (fr) * | 2010-07-29 | 2012-02-02 | Laboratoires Fournier Sa | Composes pour le traitement/la prevention des maladies inflammatoires oculaires |
Non-Patent Citations (3)
| Title |
|---|
| BEYAZYILDIZ Е. et al. Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome * |
| LI R. et al. An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopoloamine-Induced Dry Eye//ARVO Annual Meeting Abstract, April 2009, Volume 50, Issue 13, 3661, . * |
| LI R. et al. An NGF Mimetic, MIM-D3, Demonstrates Therapeutic Efficacy in a Rat Model of Scopoloamine-Induced Dry Eye//ARVO Annual Meeting Abstract, April 2009, Volume 50, Issue 13, 3661, реферат. BEYAZYILDIZ Е. et al. Efficacy of Topical Mesenchymal Stem Cell Therapy in the Treatment of Experimental Dry Eye Syndrome Model//Stem Cells Int. 2014; 2014: 250230.Published online 2014 Jul 17. doi: 10.1155/2014/250230. * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL252077A0 (en) | 2017-07-31 |
| AU2015355169A1 (en) | 2017-05-25 |
| ZA201703052B (en) | 2019-03-27 |
| RU2017118978A (ru) | 2019-01-09 |
| EP3226853B1 (en) | 2019-09-04 |
| JP6692808B2 (ja) | 2020-05-13 |
| RU2017118978A3 (https=) | 2019-06-04 |
| EP3226853A1 (en) | 2017-10-11 |
| SG11201703572SA (en) | 2017-05-30 |
| CN107106553A (zh) | 2017-08-29 |
| KR20170100483A (ko) | 2017-09-04 |
| JP2018500546A (ja) | 2018-01-11 |
| MX2017007295A (es) | 2018-03-12 |
| WO2016089807A1 (en) | 2016-06-09 |
| ES2759729T3 (es) | 2020-05-12 |
| CA2967432A1 (en) | 2016-06-09 |
| US20170360013A1 (en) | 2017-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2706787C2 (ru) | Модель сухого кератоконъюнктивита на животных и способы применения таких животных | |
| De Paiva et al. | Dry eye–induced conjunctival epithelial squamous metaplasia is modulated by interferon-γ | |
| Yu et al. | Neurokinin-1 receptor antagonism ameliorates dry eye disease by inhibiting antigen-presenting cell maturation and T helper 17 cell activation | |
| Solomon et al. | Pro-and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease | |
| Keane–Myers et al. | Prevention of allergic eye disease by treatment with IL-1 receptor antagonist | |
| Reins et al. | MyD88 deficiency protects against dry eye–induced damage | |
| Ciprandi et al. | Terfenadine exerts antiallergic activity reducing ICAM‐1 expression on nasal epithelial cells in patients with pollen allergy | |
| Goldberg et al. | G-CSF and neutrophils are nonredundant mediators of murine experimental autoimmune uveoretinitis | |
| Dietrich et al. | Comparative analysis on the dynamic of lacrimal gland damage and regeneration after Interleukin-1α or duct ligation induced dry eye disease in mice | |
| Vitar et al. | Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model | |
| Jin et al. | Anti-inflammatory effects of glycine thymosin β4 eye drops in experimental dry eye | |
| Turner et al. | STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis | |
| Hosotani et al. | IL-33-induced keratoconjunctivitis is mediated by group 2 innate lymphoid cells in mice | |
| Okada et al. | TNFalpha suppression of corneal epithelium migration | |
| CN114555107A (zh) | 用于干眼病的tsg6多肽片段 | |
| Tan et al. | Ocular pathogenesis and immune reaction after intravitreal dispase injection in mice | |
| Trinh et al. | Th1-and Th2-related chemokine and chemokine receptor expression on the ocular surface in endotoxin-induced uveitis | |
| Wang et al. | Th22 cells induce Müller cell activation via the Act1/TRAF6 pathway in diabetic retinopathy | |
| JP5800263B2 (ja) | アレルギー性鼻炎治療剤のスクリーニング方法およびその利用 | |
| Atef et al. | Interleukin-36α Expression in Vitiligo Skin Lesions and Its Association with Disease Pattern, Activity, and Severity | |
| Tu et al. | THBS1 inhibition alleviates inflammatory response by inhibiting TGF-β and NLRP3 inflammasome in experimental murine dry eye | |
| Kulualp et al. | Therapeutic effect of bovine amniotic fluid in murine dry eye model | |
| Huo et al. | Influence of plasma exchange on transplantation related immune function in patients with liver failure | |
| US9782385B2 (en) | Artificial tears solution combination | |
| Xing et al. | Heme oxygenase-1-enriched tolerogenic dendritic cell-derived exosomes attenuate lupus nephritis by restoring immune balance and iron homeostasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201202 |